Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication
https://www.zacks.com/stock/news/2224200/ionis-ions-eplontersen-gets-fast-track-tag-for-new-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2224200
Feb 09, 2024 - The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
0
Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals
https://www.zacks.com/stock/news/2224190/pharma-stock-roundup-azn-lly-s-q4-earnings-nvo-nvs-mrk-s-m-a-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2224190
Feb 09, 2024 - Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.
0
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
https://www.zacks.com/stock/news/2227354/ironwood-irwd-q4-earnings-miss-revenues-beat-marginally?cid=CS-ZC-FT-analyst_blog|earnings_article-2227354
Feb 16, 2024 - Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.
0
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
https://www.zacks.com/stock/news/2234914/astrazeneca-azn-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2234914
Mar 01, 2024 - In the closing of the recent trading day, Astrazeneca (AZN) stood at $64.60, denoting a +0.69% change from the preceding trading day.
0
AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion
https://www.zacks.com/stock/news/2240793/astrazeneca-azn-to-acquire-amolyt-pharma-for-1-05-billion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240793
Mar 14, 2024 - AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latter's late-stage hypoparathyroidism treatment candidate, eneboparatide.
0
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azn-s-new-acquisition-fda-updates-for-nvo-lly-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2241296
Mar 15, 2024 - AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
0
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US
https://www.zacks.com/stock/news/2243035/astrazeneca-azn-follows-boehringer-to-cap-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243035
Mar 19, 2024 - AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
0
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US
https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405
Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
0
Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study
https://www.zacks.com/stock/news/2244951/merck-s-mrk-keytruda-lynparza-combo-fails-2nd-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244951
Mar 22, 2024 - Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.
0
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates
https://www.zacks.com/stock/news/2245062/pharma-stock-roundup-azn-to-buy-fusn-pfe-to-sell-stake-in-hln-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2245062
Mar 22, 2024 - AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
0